(Q38184849)

30 August 2017

The mechanism of action of BCG therapy for bladder cancer--a current perspective (English)

1 reference

30 August 2017

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24492433%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

author name string

Gil Redelman-Sidi

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24492433%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Michael S Glickman

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24492433%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

language of work or name

English

0 references

publication date

4 February 2014

1 reference

30 August 2017

Nature Reviews Urology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24492433%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24492433%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

page(s)

153-162

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24492433%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24492433%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrurol.2014.15

3 June 2020

exact match

0 references

cites work

Immunotherapeutic strategies for high-risk bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Effect of Bacillus Calmette-Guérin Infection on Transplanted Tumours in the Mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

An endotoxin-induced serum factor that causes necrosis of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Immunotherapy of cancer: regression of tumors after intralesional injection of living Mycobacterium bovis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

ICUD-EAU International Consultation on Bladder Cancer 2012: Urothelial carcinoma of the prostate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

The role of granulocytes following intravesical BCG prophylaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

TRAIL and apoptosis induction by TNF-family death receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Enhancing effect of an inhibitor of nitric oxide synthesis on bacillus Calmette-Guerin-induced macrophage cytotoxicity against murine bladder cancer cell line MBT-2 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Monocyte-derived macrophage cytokine responses induced by M. bovis BCG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Macrophages are a significant source of type 1 cytokines during mycobacterial infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Urine dendritic cells: a noninvasive probe for immune activity in bladder cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Bacillus Calmette-Guérin-pulsed dendritic cells stimulate natural killer T cells and gammadeltaT cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

A possible mechanism of intravesical BCG therapy for human bladder carcinoma: involvement of innate effector cells for the inhibition of tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Immune suppression in the tumor microenvironment: a role for dendritic cell-mediated tolerization of T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Role of Th1 and Th2 cytokines in BCG-induced IFN-gamma production: cytokine promotion and simulation of BCG effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Recombinant bacillus Calmette-Guérin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Anti-interleukin-10R1 monoclonal antibody enhances bacillus Calmette-Guérin induced T-helper type 1 immune responses and antitumor immunity in a mouse orthotopic model of bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guérin-induced antitumor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Markers predicting response to bacillus Calmette-Guérin immunotherapy in high-risk bladder cancer patients: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Mycobacterial interaction with innate receptors: TLRs, C-type lectins, and NLRs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Toll-like receptors in normal and malignant human bladders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Innate immune recognition of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Identification of the mycobacterial subcomponents involved in the release of tumor necrosis factor-related apoptosis-inducing ligand from human neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guérin: involvement of toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Specific binding of bacillus Calmette-Guérin to urothelial tumor cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

The effect of intravesical instillation of antifibrinolytic agents on bacillus Calmette-Guerin treatment of superficial bladder cancer: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Characterization of the internalization of bacillus Calmette-Guerin by human bladder tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Oncogenic activation of Pak1-dependent pathway of macropinocytosis determines BCG entry into bladder cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Inhibition of mycobacterial infection by the tumor suppressor PTEN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Cytokine production by the human bladder carcinoma cell line T24 in the presence of bacillus Calmette-Guerin (BCG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Induction of ICAM 1 expression on bladder tumours by BCG immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

HLA-DR expression by high grade superficial bladder cancer treated with BCG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Efficacy of bacille Calmette-Guérin immunotherapy predicted by expression of antigen-presenting molecules and chemokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

BCG directly induces cell cycle arrest in human transitional carcinoma cell lines as a consequence of integrin cross-linking

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Bacille-Calmette Guèrin induces caspase-independent cell death in urothelial carcinoma cells together with release of the necrosis-associated chemokine high molecular group box protein 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Are BCG effects against urinary bladder carcinoma cell line T24 correlated with apoptosis in vitro?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Active immunotherapy for acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

BCG immunotherapy of malignant melanoma: summary of a seven-year experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Immunotherapy of guinea pig cancer with BCG.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guérin (BCG) immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Mycobacterium bovis bacillus Calmette-Guérin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Histological parameters and pitfalls in the interpretation of bladder biopsies in bacillus Calmette-Guerin treatment of superficial bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Requirement of a thymus dependent immune response for BCG-mediated antitumor activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

T-cell subsets required for intravesical BCG immunotherapy for bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Inhibition of murine bladder tumor growth by bacille Calmette-Guerin: lack of a role of natural killer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

NK cells are essential for effective BCG immunotherapy

31 March 2020

2 references

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

31 March 2020

12 December 2020

Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Role of Th1-stimulating cytokines in bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against mouse bladder cancer MBT-2 cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Macrophages in tumor microenvironments and the progression of tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Induction of TH1- and TH2-associated cytokine mRNA in mouse bladder following intravesical growth of the murine bladder tumor MB49 and BCG immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Gu�rin immunotherapy for carcinoma in situ of the bladder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Predictive value of urinary interleukin-8 cutoff point for recurrences after transurethral resection plus induction bacillus Calmette-Guérin treatment in non-muscle-invasive bladder tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Prognostic value of purified protein derivative skin test and granuloma formation in patients treated with intravesical bacillus Calmette-Guerin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Systemic immune response after intravesical instillation of bacille Calmette-Guérin (BCG) for superficial bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Role of a bacillus Calmette-Guérin fibronectin attachment protein in BCG-induced antitumor activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Role of urothelial cells in BCG immunotherapy for superficial bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Internalization of bacille Calmette-Guerin by bladder tumor cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Bacillus-Calmette-Guérin (BCG) and 3D tumors: an in vitro model for the study of adhesion and invasion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Effects of bacillus Calmette-Guèrin and interferon alpha-2B on cytokine production in human bladder cancer cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Local immune responses after intravesical BCG treatment for carcinoma in situ

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Surface antigen expression on bladder tumor cells induced by bacillus Calmette-Guérin (BCG): A role of BCG internalization into tumor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.15

Cathepsin B is involved in the apoptosis intrinsic pathway induced by Bacillus Calmette-Guérin in transitional cancer cell lines

31 March 2020

1 reference

12 December 2020

Significance of target cell infection and natural killer cells in the anti-tumor effects of bacillus Calmette-Guerin in murine bladder cancer.

1 reference

12 December 2020

Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guérin-activated killer cells.

1 reference

12 December 2020

Urinary interleukin-8 predicts the response of standard and low dose intravesical bacillus Calmette-Guerin (modified Danish 1331 strain) for superficial bladder cancer

1 reference

12 December 2020

Immunological factors which influence response to immunotherapy in malignant melanoma.

1 reference

12 December 2020

The Treatment of Inoperable Sarcoma by Bacterial Toxins (the Mixed Toxins of the Streptococcus erysipelas and the Bacillus prodigiosus).

1 reference

12 December 2020

Activation of natural killer cells by Bacillus Calmette-Guérin

1 reference

12 December 2020

Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy

1 reference

12 December 2020

Macrophage receptors for Mycobacterium tuberculosis

1 reference

12 December 2020

Production of IL-5, a classical T(H)2 cytokine, following bacillus Calmette guerin immunotherapy of bladder cancer

1 reference

12 December 2020

Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value

1 reference

12 December 2020

Autocrine IL-6 production by human transitional carcinoma cells upregulates expression of the alpha5beta1 firbonectin receptor

1 reference

12 December 2020

Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin

1 reference

12 December 2020

Treatment of upper tract urothelial carcinoma: a review of surgical and adjuvant therapy.

1 reference

12 December 2020

Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2

1 reference

12 December 2020

BCG-induced interleukin-6 upregulation and BCG internalization in well and poorly differentiated human bladder cancer cell lines.

1 reference

12 December 2020

Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials

1 reference

12 December 2020

Internalization of Mycobacterium bovis, Bacillus Calmette Guerin, by bladder cancer cells is cytotoxic

1 reference

12 December 2020

Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer

1 reference

12 December 2020

Immunotherapy of cancer: regression of intradermal tumors and prevention of growth of lymph node metastases after intralesional injection of living Mycobacterium bovis

1 reference

12 December 2020

Modulation of fibronectin-mediated Bacillus Calmette-Guérin attachment to murine bladder mucosa by drugs influencing the coagulation pathways

1 reference

12 December 2020

Characterization of fibronectin attachment by a human transitional cell carcinoma line, T24.

1 reference

12 December 2020

Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guérin

1 reference

12 December 2020

The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893.

1 reference

12 December 2020

Reduction of bladder tumor growth in mice treated with intravesical Bacillus Calmette-Guérin and its correlation with Bacillus Calmette-Guérin viability and natural killer cell activity

1 reference

12 December 2020

Immunophenotypic characterization of the bladder mucosa infiltrating lymphocytes after intravesical BCG treatment for superficial bladder carcinoma

1 reference

12 December 2020

Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells

1 reference

12 December 2020

Bacillus-calmette-guerin (bcg) organisms directly alter the growth of bladder-tumor cells

1 reference

12 December 2020